Targeting metastatic upper gastrointestinal adenocarcinomas

doi:10.5306/wjco.v2.i3.135

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5273)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

337

HTML

4583

Figures (1-3)

180

Tables (1-2)

173

Sum=5273

Mar 10, 2011 (publication date) through May 24, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Mar 10, 2011; 2(3): 135-149
Published online Mar 10, 2011. doi: 10.5306/wjco.v2.i3.135

Full Size Figure Download Figure

Figure 2 Schematic representation of the vascular endothelial growth factor pathway. VEGF: Vascular endothelial growth factor; PlGF: Placental growth factor; mAb: Monocolonal antibody; VEGFR: Vascular endothelial growth factor receptor; mTOR: Mammalian target of rapamycin; PI3K: Phosphoinositide 3-kinases; MEK: MAP kinase or ERK kinase; TKI: Tyrosine kinase inhibitor.

Citation: Spratlin JL, Chu Q, Koski S, King K, Mulder K. Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011; 2(3): 135-149
URL: https://www.wjgnet.com/2218-4333/full/v2/i3/135.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i3.135